CRO PRA Health Sciences upsized one of its European outposts, investing in bioanalytical services to bolster its clinical research operations in the region.
CRO giant Quintiles posted another $1 billion revenue quarter on the way to a record year, but the company is narrowing its sales projections over ongoing foreign exchange issues.
BioClinica is changing how it does business with other CROs, the company said, responding to client demand and rolling out a new partnering program.
SRI International's CRO division signed a deal with the National Institutes of Health that could bring in up to $100 million over 5 years, agreeing to help develop therapies designed to treat the effects of radiation exposure.
India's Syngene, the recently IPO'd CRO division of Biocon, kept up its years-long run of growth with a 28% revenue boost in the second quarter of its fiscal year.
Quintiles signed a deal with healthcare information giant IMS Health to pair its own clinical development expertise with its partner's huge trove of real-world data, planning to use anonymized patient information to steer drug trials.
Quintiles, the world's largest CRO, is promoting a new chief operating officer from within and bringing on an external chief financial officer as the company rolls toward a record revenue year.
Evotec's CRO division signed a deal with the Beyond Batten Disease Foundation to help discover new potential treatments for the rare, fatal nervous disorder.
PRA Health Sciences added biotech veteran Linda Grais to its board of directors, broadening its managerial suite as it works to grow around the globe.
Contract drug developer Frontage Laboratories is expanding its business to include agrochemical testing, adding capacity in hopes of lengthening its client roster.
Cel-Sci, at work on a Phase III cancer treatment, has signed up to borrow up to $5 million as it pursues a $50 million lawsuit against former CRO partner inVentiv Health.
Contract drug developer Aesica wants to become its clients' sole point of contact among their many vendors, pitching an all-encompassing service offering.
INC Research added a new tool for early-stage safety studies, bringing in a new technology the company says will make Phase I cardiac trials more efficient.
Privately held CRO PPD scored two federal contracts tasking it with helping to improve health outcomes for active-duty soldiers and aiding with the government's stockpile of flu vaccines.
WuXi PharmaTech, working to expand the adoption of its new clinical genomics service, partnered up with a large Qatari hospital to sequence the genomes of patients and help guide treatment.
Genae, a med tech-focused CRO, opened a Japanese outpost to broaden its reach, setting up shop in Tokyo with eyes on the growing Asian market for medical devices.
Preclinical CRO Charles River Laboratories brought in three new discovery contracts with outfits funded by the Wellcome Trust, lending its expertise in early-stage drug development.
German drug developer Evotec signed a 5-year, $4.9 million agreement with the National Cancer Institute to help the group build and manage its library of potential oncology drugs.
CRO Frontage is expanding its bioanalytical labs to meet what it says is a spike in client demand, doubling its capacity.
CRO Accelovance has appointed an oncologist with deep roots in drug development to help steer its efforts in cancer R&D, replacing the company's last big get in the field.